Literature DB >> 511333

Concentrations of nystatin in faeces after oral administration of various doses of nystatin.

W Hofstra, H G de Vries-Hospers, D van der Waaij.   

Abstract

Nystatin was administered in ten healthy adult volunteers in increasing doses of 3 X 10(6) I U, 6 X 10(6) I U, 9 X 10(6) I U and 12 X 10(6) I U per day, each dose being given for a five-day period. Faecal samples were collected daily for the determination of their concentration of biologically active nystatin. Nystatin concentrations were determined biologically; the sensitivity of this method was less than or equal to 20 mcg/g of faeces. During the four treatment periods with increasing doses, 38%, 31%, 26% and 20% respectively of the faecal samples contained biologically undetectable amounts of nystatin. This means that nystatin is either inactivated or unevenly distributed through the intestinal contents, or both. The practical consequences of this may be that in a significant portion of the colon there is no inhibitory nystatin concentration against Candida albicans, despite treatment with as much as 12 X 10(6) I U of nystatin per day.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 511333     DOI: 10.1007/bf01640934

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  Critical analysis of intestinal antisepsis.

Authors:  E J POTH
Journal:  J Am Med Assoc       Date:  1957-04-13

2.  Pseudomonas septicemia: incidence, epidemiology, prevention and therapy in patients with advanced cancer.

Authors:  S C Schimpff; W H Greene; V M Young; P H Wiernik
Journal:  Eur J Cancer       Date:  1973-06       Impact factor: 9.162

3.  Gastrointestinal "sterilization" in the treatment of patients with acute leukemia.

Authors:  H D Preisler; I M Goldstein; E S Henderson
Journal:  Cancer       Date:  1970-11       Impact factor: 6.860

4.  Infectious complications in cancer patients treated with chemical immunosuppressive agents.

Authors:  D Armstrong
Journal:  Transplant Proc       Date:  1973-09       Impact factor: 1.066

5.  Oral dose and faecal concentration of antibiotics during antibiotic decontamination in mice and in a patient.

Authors:  D van der Waaij; J M Berghuis-de Vries; C Korthals Altes
Journal:  J Hyg (Lond)       Date:  1974-10

6.  Prophylactic oral antibiotics in the management of acute leukaemia.

Authors:  J A Levi; P C Vincent; F Jennis; D E Lind; F W Gunz
Journal:  Med J Aust       Date:  1973-05-26       Impact factor: 7.738

Review 7.  Mechanisms by which antibiotics increase the incidence and severity of candidiasis and alter the immunological defenses.

Authors:  M S Seelig
Journal:  Bacteriol Rev       Date:  1966-06

8.  Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

Authors:  S C Schimpff; V M Young; W H Greene; G D Vermeulen; M R Moody; P H Wiernik
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

9.  Studies of patients in a laminar air flow unit.

Authors:  G P Bodey; E J Freireich; E Frei
Journal:  Cancer       Date:  1969-11       Impact factor: 6.860

10.  Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis.

Authors:  S C Schimpff; W H Greene; V M Young; C L Fortner; N Cusack; J B Block; P H Wiernik
Journal:  Ann Intern Med       Date:  1975-03       Impact factor: 25.391

View more
  5 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  The non-enzymatic inactivation of thirteen beta-lactam antibiotics in human faeces.

Authors:  G Jansen; F Weissing; H de Vries-Hospers; R Tonk; D van der Waaij
Journal:  Infection       Date:  1992 Nov-Dec       Impact factor: 3.553

3.  The in vitro inactivation of thirteen beta-lactam antibiotics by other mechanisms than adsorption to faecal substance.

Authors:  H de Vries-Hospers; G Jansen; R Tonk; D Oenema; D van der Waaij
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

4.  Concentrations of amphotericin B in faeces and blood of healthy volunteers after the oral administration of various doses.

Authors:  W Hofstra; H G de Vries-Hospers; D van der Waaij
Journal:  Infection       Date:  1982       Impact factor: 3.553

Review 5.  Selective decontamination of the digestive tract: the mechanism of action is control of gut overgrowth.

Authors:  Luciano Silvestri; Miguel A de la Cal; Hendrick K F van Saene
Journal:  Intensive Care Med       Date:  2012-09-22       Impact factor: 17.440

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.